NASDAQ · Biotechnology · USD

Abpro Corporation (ABP) Stock Analysis

Abpro Corporation (ABP) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

ABP

$0.20

+$0.05 (+37.76%)

Last trade April 24, 2026

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare ABP with… →

ABP Key Statistics

As of Apr 24, 2026

Trading

Open: $0.17
Previous Close: $0.14
Day's Range: 0.17–0.20
52-Week Range: 0.11–18.03
Volume: 61.40K
Beta: −0.00

Valuation

Market Cap: $1.42M
P/E Ratio: unprofitable
EPS (ttm): −8.25

Financials (FY)

Profit margin: 0.00%
1-Year Return: −98.02%

Dividend and dates

Avg Volume: 1.72M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

ABP Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

Year	Return
2026 (partial year)	−95.34%
2025	−89.67%

As of April 24, 2026.

ABP Valuation vs Biotechnology Median

Median of 656 stocks

Metric	ABP	Biotechnology median	vs median
Profit margin	0.00%	0.00%	0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Analysis

Data-derived

Company Overview

Abpro Corporation (ABP) is capitalised at $1.42M on the latest close. The company sits in the Healthcare sector, in the Biotechnology industry. The company reports 6 employees.

Over the past 52 weeks the price has ranged from $0.11 to $18.03. ABP last closed at $0.20 on April 24, 2026. That is +$0.05 (+37.76%) against the previous close. The latest close sits 79.09% above that 52-week low.

Financial Health

Trailing twelve-month revenue on file is $0.00. The reported profit margin is 0%. Earnings per share on a trailing basis come to −8.25.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published.

Beta against the wider market is reported at −0. Annualized volatility over the trailing 1 year is 182.35%. The trailing one-year price return is −98.02%.

Growth & Income

The record shows no dividend for ABP.

The record holds one complete calendar year, 2025, which returned −89.67%. So far in 2026 the price is −95.34%.

Peer Comparison

Abpro Corporation (ABP) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company	Ticker	Market Cap	P/E Ratio
Abpro Corporation	ABP	$1.42M	—
Vertex Pharmaceuticals Incorporated	VRTX	$138.42B	32.5
Regeneron Pharmaceuticals, Inc.	REGN	$85.22B	20.5
argenx SE	ARGX	$64.25B	40.1

The Biotechnology industry average P/E ratio is 12.6x. Abpro Corporation has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of April 24, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

ARGX

argenx SE

$64.25B

MRNA

Moderna, Inc.

$58.11B

RVMD

Revolution Medicines, Inc.

$45.01B

ONC

BeOne Medicines AG

$40.53B

View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

JNJ

Johnson & Johnson

$663.28B

ABBV

AbbVie Inc.

$453.19B

MRK

Merck & Co., Inc.

$370.89B

UNH

UnitedHealth Group Incorporated

$356.47B

View all Healthcare stocks →

About Abpro Corporation

Abpro Holdings, Inc., a biotechnology company, focuses on novel antibody constructs for immuno-oncology and ophthalmology. Its platforms include DiversImmune, a discovery platform that generates a diverse collection of proprietary antibodies against clinically validated and novel targets; and MultiMab, an engineering platform that provides the flexibility to combine antibody building blocks in different combinations and orientations to create fit for purpose novel full-length multi-specific antibody constructs. The company's lead product candidates include ABP-102, a next generation immuno-oncology TetraBi antibody targeting HER2 and CD3 is developed for the treatment of HER2+ solid tumors, including breast and gastric cancers; and ABP-201, a TetraBi antibody format that simultaneously inhibit VEGF and ANG-2 for the treatment of vascular diseases of the eye, including diabetic macular edema and wet age-related macular degeneration. It also develops ABP-110, a TetraBi antibody targeting GPC3 and CD3 for the treatment of hepatocellular carcinoma; and ABP-150, a TetraBi antibody targeting claudin 18.2 and CD3 for the treatment of gastric cancers. The company has strategic partnership with Celltrion Inc. and Abpro Bio International, Inc. Abpro Holdings, Inc. was incorporated in 2004 and is headquartered in Woburn, Massachusetts.

Visit website →